Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel
The Target Selector™
Breast cancer is the most commonly diagnosed cancer in women and the second leading cause of cancer death among women1. It is estimated that each year over 250,000 women in
Published guidelines from the
"We are extremely pleased to launch our second multi-gene liquid biopsy panel, this one tailored to breast cancer, which expands our Target Selector family of offerings to physicians and researchers in both academic centers and the pharmaceutical industry," said
"The multi-gene panel has undergone robust and extensive analytical and clinical validation to identify all main classes of genomic aberrations encountered in breast cancer, with an overall clinical accuracy of 99.8%, specificity of greater than 99% and sensitivity of greater than 90%," he added. "
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the potential clinical utility of our proprietary technology platform, the commercial success of our Target Selector™
 Andre, F., Ismaila, N., Henry, N. L.,
 Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A.,
 Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., Jenkins, R. B., Press, M. F., Spears, P. A., Vance, G. H., Viale, G., McShane, L. M., and Dowsett, M. (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update, Archives of pathology & laboratory medicine142, 1364-1382.
LHA Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-announces-commercial-launch-of-target-selector-ngs-breast-panel-the-companys-second-multi-gene-tumor-specific-panel-300870078.html